Tyme is an easy-to-use time-tracking application for freelancers, small companies, and everyone who wants to have an overview of their working times. With Tyme you’ll be able to have an instant overview of your working hours, progress you’ve made in your projects and if you are still in time and budget.
Doom Patrol Season 1 set itself apart from the rest of the superhero shows by leaning into its eccentricities. A villainous rat and a man-dinosaur-vegetable combination are just some examples of the characters that exist within the series’ wildly imaginative universe. Doom Patroldoesn’t let up on its outlandish nature in Season 2. And with Mr. Nobody is still trapped inside a painting, Season 2 moved on without him, introducing a new villain by the name of Doctor Jonathan Tyme, a mysterious disco-loving time traveler.
Some spoilers ahead for Doom Patrol Season 2.
Doctor Tyme (aka, the Terrible Doctor Tyme) makes his grand entrance in the Season 2 episode “Tyme Patrol.” With a magical clock-shaped helmet — imagine an enlarged Mr. Cogsworth from Beauty and the Beast — and a time-altering space mineral (continuinium) in tow, the Terrible Doctor Tyme is labeled a “history-hopping madman.”
He also loves roller disco.
Rita, Cliff, and Jane find Tyme in search of the continuinium, the dangerous mineral the villain uses to time travel. The only issue is that the space mineral is inside his helmet, which is firmly on his head. (It’s complicated.)
When the Doom Patrol first meets him, they’re thrown off by the villain’s sparkly cape, the never-ending roller disco party, and Doctor Tyme’s “time ray” — a beam he shoots out of his helmet to freeze people in place. It doesn’t take very long to realize they're in way over their heads.
If you're just as confused as our heroes, here's a quick explainer on one of the weirdest supervillains in DC Comics history.
Before becoming Doctor Tyme, he was Percival Sutter, a highly intelligent scientist specializing in the manipulation of time. After figuring out how to time travel, Sutter began using it to his benefit, committing petty theft and other small scale crime.
Doctor Tyme’s first comic book appearance was in 1964’s Doom Patrol #93: The Sinister Secret of Dr. Tyme. His attempts to rob a plane draw the attention of the Doom Patrol. Their run-in proves how formidable a villain Doctor Tyme can be, using his helmet to freeze, slow down, or stop time completely.
However, his exploits aren’t very ambitious considering the power he wields. Despite this, Doctor Tyme has an inflated sense of ego and truly believes himself to be the Doom Patrol’s greatest nemesis. However, they don’t think very much of him and consider him insignificant at best.
Unlike Mr. Nobody, Doctor Tyme doesn’t go looking for the Doom Patrol. In fact, he doesn’t seem very interested in them at all. He's too busy roller skating and partying inside a time capsule. The only reason the Doom Patrol needs him for the continuinium, which would allow Niles Caulder to live as long as his immortal daughter, Dorothy.
However, Doctor Tyme doesn’t seem like the kind of villain who will leave well enough alone. Now that the Doom Patrol have alerted him to their plans to steal his helmet, the villain might wage an offensive plan in response to thwarting his timeless fun.
While Doom Patrol’s iteration of the character seems to follow along the same path of the comics so far, it’s possible Doctor Tyme is being set up as a much more menacing foe on the show. Either that or the Doom Patrol just awakened an opportunity for the villain to stir up some trouble that he wouldn't have bothered with otherwise. Whatever the case may be, only tyme will tell.
The first three episodes of Doom Patrol Season 2 are currently available to stream on HBO Max and DC Universe.
BEDMINSTER, N.J.--(BUSINESS WIRE)--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTsTM), announced that the final results of its SM-88 Phase II Prostate Cancer study designed to evaluate the safety, tolerability and efficacy of SM-88 in patients with non-metastatic biochemical recurrent prostate cancer, was published on September 13th, 2020 in the peer-reviewed journal Investigational New Drugs. The article, titled “Phase II Trial of SM-88, a Cancer Metabolism Based Therapy, in Non-Metastatic Biochemical Recurrent Prostate Cancer,” is available online at https://doi.org/10.1007/s10637-020-00993-4.
The study demonstrated that SM-88 had promising efficacy and safety outcomes for prostate cancer patients while sparing testosterone. The study also demonstrated a reduction of CTCs, an important prognostic indicator, that may prove to be a better surrogate for patient outcomes than PSA, particularly for SM-88.
“Oral SM-88 has demonstrated potential efficacy and a well-tolerated safety profile that may represent a new treatment option for more than 450,000 prostate cancer patients in the U.S. alone seeking a non-cytotoxic, non-hormonal therapy,” said Giuseppe Del Priore, M.D., M.P.H., Chief Medical Officer at TYME. “We are encouraged by the clinical results of our unique proprietary approach using cancer metabolism-based therapies that we believe attack the cancer cells from within, interrupting the cancer metabolic processes.”
Maxon cinema 4d studio r21 026. From September 2016 to April 2019, twenty-three evaluable patients with non-metastatic pancreatic cancer with rising PSA levels, detectable circulating tumor cells and no radiographically detectable metastases were assessed in a Phase II trial. All patients received 230 mgs twice per day of SM-88 orally. Patients also received oral doses of methoxsalen (10 mg), phenytoin (50 mg), and sirolimus (0.5 mg) once per day. Most patients had previously received androgen-deprivation therapy (ADT) after radiation therapy or surgery, but ADT treatment changes were not permitted during the trial.
From the initial diagnoses of PSA rise, 100% of patients (23/23) remained free of metastatic progression (MFS) and 87% of patients (20/23) have maintained radiographic progression-free survival (rPFS) with a median duration of therapy of 6.5 months since starting SM-88 treatment. All patients who have maintained meaningful reductions in circulating tumor cells (CTCs) on SM-88 were 100% free of any radiographic progression.
At baseline, the median PSA for patients with radiographic progression was 13.4 compared to 5.6 for patients with no radiographic progression (p=0.02). Among evaluable patients, PSA stabilized in 83% of patients (19/23). Importantly, 52% of evaluable patients (12/23) experienced an improvement in median PSA doubling time (DT), a positive prognostic indicator. In all patients who completed three cycles of therapy, the median DT improved nearly 34.4% from 6.1 to 8.2 months (n=20). After 12 weeks, or three cycles of therapy, 78.2% of patients (18/23) demonstrated a decrease in CTC from baseline, with a median decrease of 65.3%.
https://freewater.mystrikingly.com/blog/pdf-bearbeiten-kostenlos-mac. Patients without local progression (20/23) had slightly higher testosterone levels at baseline and throughout treatment on SM-88 as compared to those who experienced local radiographic progression (3/23). According to the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, patients generally reported stable cognitive and sexual function domain measures, with no detectable worsening in any domain. Patient weight, EKG QTc, glucose and hematocrit and other measures, which are often side effects of ADT, did not appear affected while receiving SM-88.
The SM-88 therapy was well tolerated in all patients. There were no treatment-related serious adverse events. No adverse events resulted in dose delay, discontinuation, or reduction. The majority of Grade 1 AEs possibly or probably related to the SM-88 investigational therapy were gastrointestinal in nature.
The Phase II prostate cancer trial results are from an investigational study. SM-88 is not approved for the treatment of patients with any disease condition.
About Advanced Prostate Cancer
Prostate cancer is the most common malignancy in men, accounting for approximately 31,620 deaths in the United States in 2019.1 Approximately 15% of men with prostate cancer present with metastatic disease, and 20% to 30% of men with localized disease treated with definitive local therapy subsequently develop metastatic disease. While the vast majority of patients with metastatic disease demonstrate a transient response to androgen deprivation, eventually all patients develop hormone refractory prostate cancer (HRPC) and virtually all prostate cancer deaths are due to the development of metastatic HRPC.2 While chemotherapy regimens have shown a modest survival advantage in HRPC patients, median survival remains approximately 19 months,3,4 and not all patients are candidates for chemotherapy. Novel agents and new approaches such as oral cancer metabolic-based therapies are needed.
About SM-88
SM-88 is an oral investigational modified proprietary tyrosine derivative that is believed to interrupt the metabolic processes of cancer cells by breaking down the cells’ key defenses and leading to cell death through oxidative stress and exposure to the body’s natural immune system. Clinical trial data have shown that SM-88 has demonstrated encouraging tumor responses across 15 different cancers, including pancreatic, lung, breast, prostate and sarcoma cancers with minimal serious grade 3 or higher adverse events. SM-88 is an investigational therapy that is not approved for any indication in any disease. Learn more.
About Tyme Technologies
Tyme Technologies, Inc., is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company’s cancer metabolism-based approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system. For more information, visit www.tymeinc.com. Follow us on social media: @tyme_Inc, LinkedIn, Instagram, Facebook and YouTube.
Forward-Looking Statements/Disclosure Notice
In addition to historical information, this press release contains forward-looking statements under the Private Securities Litigation Reform Act that involve substantial risks and uncertainties. Such forward-looking statements within this press release include, without limitation, statements regarding our drug candidates, including SM-88 and TYME-18, and their clinical potential and non-toxic safety profiles, our drug development plans and strategies, ongoing and planned preclinical and clinical trials, including the proposed TYME-19 proof-of-concept study, preliminary data results and the therapeutic design and mechanisms of our drug candidates; and readers can identify forward-looking statements by sentences or passages involving the use of terms such as “believes,” “expects,” “hopes,” “may,” “will,” “plan,” “intends,” “estimates,” “could,” “should,” “would,” “continue,” “seeks,” or “anticipates,” and similar words including their use in the negative or by discussions of future matters such as effect of the novel coronavirus (COVID-19) pandemic and the associated economic downturn and impacts on the Company's ongoing clinical trials and ability to analyze data from those trials, the cost of development and potential commercialization of our lead drug candidate and of other new products, expected releases of interim or final data from our clinical trials, possible collaborations, the timing, scope and objectives of our ongoing and planned clinical trials and other statements that are not historical. The forward-looking statements contained in this press release are based on management’s current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of TYME’s control. These statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any historical results and future results, performances or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the severity, duration, and economic impact of the COVID-19 pandemic; that the information is of a preliminary nature and may be subject to change; uncertainties inherent in the cost and outcomes of research and development, including the cost and availability of acceptable-quality clinical supply and the ability to achieve adequate clinical study design and start and completion dates; the possibility of unfavorable study results, including unfavorable new clinical data and additional analyses of existing data; risks associated with early, initial data, including the risk that the final data from any clinical trial may differ from prior or preliminary study data; final results of additional clinical trials that may be different from the preliminary data analysis and may not support further clinical development; that past reported data are not necessarily predictive of future patient or clinical data outcomes; whether and when any applications or other submissions for SM-88 may be filed with regulatory authorities; whether and when regulatory authorities may approve any applications or submissions; decisions by regulatory authorities regarding labeling and other matters that could affect commercial availability of SM-88; the ability of TYME and its collaborators to develop and realize collaborative synergies; competitive developments; and the factors described in the section captioned “Risk Factors” of TYME’s Annual Report on Form 10-K filed with the U.S. Doctor 1 1 0 – convert your documents without. Securities and Exchange Commission on May 22, 2020, as well as subsequent reports we file from time to time with the U.S. Securities and Exchange Commission available at www.sec.gov.
The information contained in this press release is as of its release date and TYME assumes no obligation to update forward-looking statements contained in this release as a result of future events or developments. https://bestwfil453.weebly.com/use-camera-on-macbook-air.html.
1https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html |
2Vogelzang N: One hundred thirteen men with prostate cancer died today. J Clin Oncol 14::1753,1996-1755 |
3Tannock IF, deWit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351::1502,2004-1512 |
4Petrylak D, Tangen CM, Hussain MH, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone in hormone refractory prostate cancer. N Engl J Med 351::1513,2004-1520 |
0 
Star